Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 1741 AL 1755

Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer's Disease

Karima S, Aghamollaii V, Mahmoodi Baram S, Balenci L, Lanctôt KL, Kiss A, Tafakhori A, Mahdavi M, Rajaei S, Shateri S, Yarhoseini A, Mokhtari F, Fotouhi A, Riazi A.

J Alzheimers Dis. 2023;94(1):359-370. doi: 10.3233/JAD-221026.

MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease

Filippi M, Cecchetti G, Agosta F.

Curr Opin Neurol. 2023 Aug 1;36(4):239-244. doi: 10.1097/WCO.0000000000001177. Epub 2023 Jun 23.

A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis

Liu L, Sun S, Kang W, Wu S, Lin L.

Rev Neurosci. 2023 Jul 10;35(2):121-139. doi: 10.1515/revneuro-2023-0033. Print 2024 Feb 26.

Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis

Jeremic D, Navarro-López JD, Jiménez-Díaz L.

Ageing Res Rev. 2023 Sep;90:102012. doi: 10.1016/j.arr.2023.102012. Epub 2023 Jul 7.

The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer's Disease Treatment

Ghareghani M, Rivest S.

Int J Mol Sci. 2023 Jun 30;24(13):10905. doi: 10.3390/ijms241310905.

Obstructive sleep apnea and dementia: A role to play?

Kinugawa K.

Rev Neurol (Paris). 2023 Oct;179(7):793-803. doi: 10.1016/j.neurol.2023.08.006. Epub 2023 Aug 24.

Anti-amyloid antibody treatments for Alzheimer's disease

Perneczky R, Dom G, Chan A, Falkai P, Bassetti C.

Eur J Neurol. 2024 Feb;31(2):e16049. doi: 10.1111/ene.16049. Epub 2023 Sep 11.

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Veitch DP, Weiner MW, Miller M, Aisen PS, Ashford MA, Beckett LA, Green RC, Harvey D, Jack CR Jr, Jagust W, Landau SM, Morris JC, Nho KT, Nosheny R, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin A, Shaw LM, Toga AW, Tosun D; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12.

Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification

Cummings JL, Osse AML, Kinney JW.

Drugs. 2023 Oct;83(15):1387-1408. doi: 10.1007/s40265-023-01938-w. Epub 2023 Sep 20.

Exosomes in multiple sclerosis and Alzheimer's disease - Adversary and ally

Tang N.

Biomed J. 2024 Oct;47(5):100665. doi: 10.1016/j.bj.2023.100665. Epub 2023 Sep 29.

Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective

Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Khalifa AA, Saad HM, Batiha GE.

J Cell Mol Med. 2024 Jan;28(2):e17993. doi: 10.1111/jcmm.17993. Epub 2023 Oct 17.

Accelerating Alzheimer's therapeutic development: The past and future of clinical trials

Boxer AL, Sperling R.

Cell. 2023 Oct 26;186(22):4757-4772. doi: 10.1016/j.cell.2023.09.023. Epub 2023 Oct 16.

The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging

Owen M, Bose N, Nisenbaum L, Partrick KA, Fillit HM.

J Prev Alzheimers Dis. 2023;10(4):729-742. doi: 10.14283/jpad.2023.111.

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

Edwards AL, Collins JA, Junge C, Kordasiewicz H, Mignon L, Wu S, Li Y, Lin L, DuBois J, Hutchison RM, Ziogas N, Shulman M, Martarello L, Graham D, Lane R, Budd Haeberlein S, Beaver J.

JAMA Neurol. 2023 Dec 1;80(12):1344-1352. doi: 10.1001/jamaneurol.2023.3861.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias